Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report)’s stock price hit a new 52-week high on Friday after HC Wainwright raised their price target on the stock from $28.00 to $50.00. HC Wainwright currently has a buy rating on the stock. Sutro Biopharma traded as high as $43.85 and last traded at $39.2410, with a volume of 28268 shares traded. The stock had previously closed at $38.42.
STRO has been the topic of a number of other research reports. Leerink Partners began coverage on Sutro Biopharma in a research report on Tuesday, April 7th. They set an “outperform” rating and a $38.00 target price on the stock. Wall Street Zen raised shares of Sutro Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Lifesci Capital raised shares of Sutro Biopharma to a “strong-buy” rating in a report on Friday, May 1st. Wells Fargo & Company upgraded shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $8.00 to $27.00 in a research report on Tuesday, March 24th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Sutro Biopharma from $51.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.78.
Check Out Our Latest Stock Analysis on STRO
Hedge Funds Weigh In On Sutro Biopharma
Sutro Biopharma Stock Performance
The company has a 50 day moving average of $28.84 and a 200-day moving average of $18.14. The stock has a market cap of $682.27 million, a price-to-earnings ratio of -1.58 and a beta of 1.63.
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The business had revenue of $14.52 million for the quarter, compared to the consensus estimate of $8.89 million. On average, research analysts anticipate that Sutro Biopharma, Inc. will post -9.04 EPS for the current year.
About Sutro Biopharma
Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.
Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.
Featured Stories
- Five stocks we like better than Sutro Biopharma
- 3 AI Data Center Stocks Worth Watching for Capital Rotation
- McDonald’s Is the Cheapest It’s Been in Years—Does That Make It a Buy?
- Karman: Defense Darling’s Outlook Strengthens After 40% Drop
- Aeluma’s Post-Earnings Dip Creates a Buying Opportunity
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
